Product
ARC1905
2 clinical trials
1 indication
Indication
Age-related macular degenerationClinical trial
A Phase 1 Ascending Dose And Parallel Group Trial To Establish The Safety, Tolerability AND Pharmacokinetic Profile Of Multiple Intravitreous Injections Of ARC1905 (ANTI-C5 APTAMER) Given Either In Combination Therapy With Multiple Doses Of Lucentis® 0.5 mg/Eye, Or With One Induction Dose Of Lucentis® 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular DegenerationStatus: Completed, Estimated PCD: 2011-03-01
Clinical trial
A Phase I Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular DegenerationStatus: Completed, Estimated PCD: 2012-11-01